ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2019 and some content may be unavailable. To unlock all content for 2019, please visit the archives.

Abstract: SA-PO902

Opioid Utilization for Pain Management Among Medicare Fee-for-Service Beneficiaries with ESRD in 2016

Session Information

  • CKD: Pharmacoepidemiology
    November 09, 2019 | Location: Exhibit Hall, Walter E. Washington Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Health Maintenance, Nutrition, and Metabolism

  • 1300 Health Maintenance, Nutrition, and Metabolism

Authors

  • Maciejewski, Matthew L., VA HSR&D, Durham, North Carolina, United States
  • Zepel, Lindsay, Duke University, Durham, North Carolina, United States
  • Wang, Virginia, Durham VA Health Care System, Duke University, Durham, North Carolina, United States
  • Diamantidis, Clarissa Jonas, Duke University School of Medicine, Durham, North Carolina, United States
  • Olin, Serene, NCQA, Washington, District of Columbia, United States
  • Blaz, Jacquelyn, National Committee for Quality Assurance, Washington, District of Columbia, United States
  • Wilson-Frederick, Shondelle, CMS, Baltimore, Maryland, United States
  • Smith, Valerie A., Duke University, Durham, North Carolina, United States
Background

Opioid misuse has raised concerns about opioid utilization under the Part D drug prescription benefit for Medicare beneficiaries. It is important to understand whether Medicare Fee-for-Service (FFS) beneficiaries with end-stage renal disease (ESRD) are more likely to utilize opioids compared to other beneficiaries.

Methods

We assembled a 100% Medicare FFS sample (n=20,880,490) with 12-month Part A, B, and D coverage between 1/1/2016-12/31/2016 to examine patient factors associated with 2 opioid utilization outcomes. We used a two-part model to estimate the probability of opioid utilization in 2016 via logistic regression and the level of average daily dose (ADD)≥120 morphine milligram equivalents (MME) via a generalized linear model with a gamma distribution and identity link in those with >1 opioid prescription. Beneficiary characteristics (age, disability, ESRD, dual eligibility, race and ethnicity, rurality, 16 chronic conditions) were adjusted.

Results

35% of FFS beneficiaries had 1 or more opioid prescription fills in 2016 and 1.5% had ADDs≥120 MME. Compared to age-eligible beneficiaries without ESRD, beneficiaries were more likely to fill opioids if they were disabled with ESRD (odds ratio (OR)=2.57, 95% confidence interval (CI): 2.53, 2.61) or without ESRD (OR=1.43, 95% CI: 1.42, 1.43), age eligible with ESRD (OR=1.99, 95% CI: 1.96, 2.02), or eligible due to ESRD alone (OR=2.31, 95% CI: 2.25, 2.37). Beneficiaries who were disabled without ESRD (OR=2.99, 95% CI: 2.95, 3.03) or with ESRD (OR=1.34, 95% CI: 1.29, 1.40) had higher odds of having ADDs≥120 MME, while beneficiaries who were age-eligible with ESRD (OR=0.71, 95% CI: 0.66, 0.76) had lower odds compared to those age-eligible without ESRD.

Conclusion

Beneficiaries who are vulnerable due to ESRD filled opioid prescriptions at higher rates than other beneficiaries and at ADDs ≥120 MME. Based on recently endorsed opioid-related quality metrics and more restricted policies on opioid dispensing, these beneficiaries should be prioritized for opioid optimization strategies to balance pain management and adverse event risk.

Funding

  • Veterans Affairs Support